Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA CRC-203 pumitamig plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated unresectable or metastatic colorectal cancer
2025-523224-45-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Pumitamig plus chemotherapy with Bevacizumab plus chemotherapy (2 arms). Primary endpoints: Overall response, Progression-free survival and 1 more. Planned start Mar 2026; status: authorised.
02
Drugs
pumitamigbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-523224-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523224-45-00.